Group 1: Financial Performance - In Q3 2025, the company achieved an operating revenue of 622.11 million yuan, representing a year-on-year growth of 4.22% [2] - The net profit attributable to shareholders reached 38.4 million yuan, with a year-on-year increase of 31.41% [2] - The net profit excluding non-recurring items grew by 36.83% [2] Group 2: Business Collaboration and Expansion - Following its integration into the General Technology Group, the company has accelerated business collaboration with medical institutions, successfully opening 138 accounts across 25 provinces by the end of September 2025 [2] - The company has enhanced its creditworthiness, leading to broader financing channels and a noticeable decrease in financing costs [2] Group 3: Pharmaceutical Operations - The company is one of three national wholesale enterprises for narcotic and psychotropic drugs, holding regional wholesale qualifications in 15 provinces, with a sales network covering 31 provinces and autonomous regions [3] - The company has a competitive advantage in narcotic drug distribution in regions such as Sichuan, Chongqing, Guizhou, Qinghai, and Tibet [3] Group 4: Retail Operations - By the end of September 2025, the company operated retail pharmacies across 22 provinces, municipalities, and autonomous regions, including 210 community health pharmacies and 832 DTP prescription pharmacies [3] - The company plans to strengthen its retail omnichannel construction and enhance its nationwide network layout, focusing on multi-dimensional marketing services and patient management systems [3]

京东健康股份有限公司是中国最大的在线医疗健康平台,也是医疗产业链数字化改造的领跑者,致力于打 造以医药及健康产品供应为核心,医疗服务为抓手,数字驱动的用户全生命周期全场景的健康管理平台。 其零售药房和在线医疗健康服务业务可以满足用户对于健康领域的各方面需求,让国民享有易得、便 捷、优质和可负担的医疗健康产品与服务。 截至8月6日收盘，京东健康（06618.HK）报52.300港元，较上个交易日上涨2.65%，当日盘中最高价触 及52.600港元，创近一年新高。 资金流向方面，当日主力流入NaN万港元，流出NaN万港元，净流入4756.55万港元。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来源：金融界 ...